Premium
Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy
Author(s) -
Wald N. J.,
George L.,
Smith D.,
Densem J. W.,
Pettersonm K.
Publication year - 1996
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1996.tb09765.x
Subject(s) - pregnancy , medicine , obstetrics , pregnancy associated plasma protein a , fetus , down syndrome , gestational age , gynecology , first trimester , biology , genetics , psychiatry
Objective To determine the value of serum screening for Down's syndrome at 8–14 weeks of pregnancy using seven potential serum markers (alpha‐fetoprotein, unconjugated oestriol, total human chorionic gonadotrophin (hCG), free α‐hCG, free P‐hCG, pregnancy associated plasma protein A (PAPP‐A), and dimeric inhibin A). Design Stored blood samples collected from women at about 10 weeks of pregnancy, prior to having a chorionic villus sampling procedure on account of advanced maternal age, were retrieved from pregnancies associated with Down's syndrome and from matched unaffected pregnancies. Setting Twenty‐one obstetric centres in nine countries. Subjects Seventy‐seven pregnancies associated with Down's syndrome each matched with five controls (except in two cases that were matched with four controls) for maternal age (same five year age groups), duration of storage of the serum sample (same calendar year), and gestational age (usually same week of pregnancy). Results The levels of two potential markers differed between affected and unaffected pregnancies sufficiently to be of value in screening—free β‐hCG and PAPP‐A. The median free P‐hCG level in affected pregnancies was 1.79 times the median level for unaffected pregnancies, and the median PAPP‐A level was 0.43 times the normal median. These two markers were combined with maternal age to estimate a woman's risk of having a fetus with Down's syndrome. A screening programme that used a risk cutoff level of 1:300 would detect 63 % of affected pregnancies and also classify 5.5% of unaffected pregnancies as screen positive. None of the other five markers added more than 2 % detection for the same false‐positive rate. Conclusion The performance of screening using maternal age and serum‐free β‐hCG and PAPP‐A at 10 weeks of pregnancy was better than the double test (alpha‐fetoprotein and hCG with maternal age) and similar to the triple test (alpha‐fetoprotein, unconjugated oestriol and hCG with maternal age) at 15–22 weeks.